Isolation of Nuclei from Human Intermuscular Adipose Tissue and Downstream Single-Nuclei RNA Sequencing
3 Mayıs 2024
1.6K görüntüleme
The biology of intermuscular adipose tissue (IMAT) is largely unexplored due to the limited accessibility of human tissue. Here, we present a detailed protocol for nuclei isolation and library preparation of frozen human IMAT for single nuclei RNA sequencing to identify the cellular composition of this unique adipose depot.
Overview
This study investigates the cellular composition and specific transcriptional profiles of intermuscular adipose tissue (IMAT) in humans, a less-explored area due to limited tissue accessibility. A detailed protocol for nuclei isolation and library preparation for single nuclei RNA sequencing is presented to facilitate the identification of cellular components within this unique adipose depot.
Key Study Components
Research Area
- Intermuscular adipose tissue (IMAT) biology
- Cellular composition and function
- Impact on metabolic diseases
Background
- IMAT is an ectopic adipose depot located between muscle fibers.
- Its volume increases with age and BMI, correlating with muscle degenerative diseases.
- Secretion of proteins from IMAT influences insulin sensitivity and inflammation in skeletal muscle.
Methods Used
- Nuclei isolation from small samples of human IMAT tissue
- Single nuclei RNA sequencing
- Protocol development for handling lipid-laden adipose tissue
Main Results
- Developed a protocol enabling researchers to analyze the cell-specific transcriptomics of IMAT.
- Facilitated identification of cellular alterations in metabolic disease states and interventions.
- Improved understanding of IMAT’s role in metabolic health.
Conclusions
- The study provides valuable insights into the biology of IMAT.
- Findings may guide novel therapeutic strategies targeting IMAT in metabolic diseases.
Frequently Asked Questions
What is intermuscular adipose tissue (IMAT)?
IMAT is an ectopic fat depot located between and around muscle fibers, which has implications in metabolic health.
Why is IMAT research important?
Understanding IMAT can provide insights into its role in insulin sensitivity and muscle associated diseases.
What methodology was developed in this study?
A specific protocol for nuclei isolation and single nuclei RNA sequencing was developed to study IMAT.
How does IMAT relate to metabolic diseases?
Increased IMAT has been associated with higher BMI and age, contributing to muscle degenerative diseases and metabolic issues.
What potential applications could arise from this research?
The findings could lead to new therapeutic strategies for targeting IMAT to alleviate metabolic diseases.
How does the study contribute to the field of biology?
It addresses significant gaps in the research concerning the biology of IMAT and its effects on metabolic health.
Executive Industry Relevance
Single-nuclei RNA sequencing of human intermuscular adipose tissue (IMAT) addresses a critical gap in understanding depot-specific cellular composition and transcriptional states relevant to metabolic and muscle degenerative diseases. This protocol enables high-resolution profiling from limited biopsy material, supporting predictive confidence in early discovery and target validation for metabolic disease portfolios. The approach enhances mechanistic de-risking at the intersection of adipose and muscle biology, informing translational research and therapeutic strategy development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of IMAT-specific cellular heterogeneity and transcriptional programs.
- Supports functional target validation by revealing cell-type-specific gene expression signatures.
- Facilitates mechanistic de-risking for metabolic and muscle disease targets.
- Provides foundational data for prioritizing depot-specific intervention strategies.
Screening & Assay Development
- Prepares validated nuclei suspensions suitable for high-throughput single-nuclei RNA-seq workflows.
- Standardizes sample processing from lipid-rich, limited human tissue biopsies.
- Enables reproducible detection of rare and low-abundance cell populations.
- Supports quantitative transcriptomic readouts for downstream compound evaluation.
Translational & Preclinical Research
- Aligns IMAT cellular profiles with disease-relevant metabolic and muscle phenotypes.
- Enables continuity from human tissue discovery to preclinical model validation.
- Supports identification of translational biomarkers linked to IMAT biology.
- Informs risk-adjusted advancement of depot-targeted therapeutic programs.
Pipeline & Workflow Integration
This nuclei isolation and sequencing protocol integrates into the discovery-to-preclinical continuum for metabolic and muscle disease research, enabling robust target validation and translational continuity.
- Discovery Biology: Supports hypothesis testing on IMAT cellular composition and secretome influence on muscle tissue.
- Screening: Delivers standardized, reproducible nuclei preparations for scalable transcriptomic assays.
- Analytics: Provides quantitative single-nuclei RNA-seq data for comparative analysis across disease states and interventions.
- Translational Research: Bridges human tissue findings to preclinical model development and biomarker discovery.
- Enterprise Reuse: Establishes a reusable protocol for profiling other challenging adipose depots or limited biopsy samples.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in IMAT-related target selection and mechanistic understanding.
- Operational Value: Standardizes nuclei isolation from lipid-rich, limited human tissues for reproducible downstream analysis.
- Strategic Value: Enables informed go/no-go decisions for depot-targeted therapeutic programs and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization of metabolic and muscle disease assets based on human tissue data.
Implementation Considerations
- Requires expertise in tissue handling, nuclei isolation, and single-nuclei RNA-seq library preparation.
- Demands access to specialized instrumentation for nuclei counting and droplet-based sequencing.
- Necessitates cross-team standardization for sample processing and data analysis workflows.
- May require adaptation for other adipose depots or tissue types with distinct lipid content.
- Limited by the amount and quality of human biopsy material available for analysis.
Biopharma FAQs
Why does null hypothesis testing matter for IMAT cell-type validation?
Null hypothesis testing enables rigorous assessment of whether observed transcriptional differences in IMAT nuclei are statistically significant, supporting confident target validation and reducing false discovery risk in early discovery pipelines.
How does independent variable isolation fit the IMAT nuclei workflow?
Isolating nuclei from IMAT minimizes confounding from adjacent muscle or fascia, ensuring that downstream transcriptomic analyses reflect true depot-specific cellular states and support accurate biological interpretation.
What do quantitative dependent variable measurements enable in IMAT profiling?
Quantitative single-nuclei RNA-seq outputs allow for precise comparison of gene expression across cell types, disease states, and interventions, enabling robust identification of rare populations and actionable molecular signatures.
Why are replication requirements critical for IMAT nuclei sequencing studies?
Replication across multiple IMAT samples ensures reproducibility and cross-functional confidence in findings, supporting collaborative decision-making and reducing risk of spurious associations in translational research.
What statistical analysis capabilities are required before IMAT data implementation?
Robust statistical tools are needed to analyze high-dimensional single-nuclei RNA-seq data, control for batch effects, and validate cell-type-specific findings before integrating results into portfolio decision workflows.
